Orforglipron
ACHIEVE-4
Eli Lilly · Phase 3 · Completed · Enrollment 2749
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Orforglipron | Obesity + T2D | n/r | n/r | n/r | n/r |
| Insulin Glargine | Obesity + T2D | n/r | n/r | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Orforglipron
Eli Lilly · Phase 3 · Completed · Enrollment 2749
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Orforglipron | Obesity + T2D | n/r | n/r | n/r | n/r |
| Insulin Glargine | Obesity + T2D | n/r | n/r | n/r | n/r |